Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

07.07.17	UK Supreme Court Rules In Favor Of Lilly On Alimta Vitamin Regimen Patents (RTTNews)
07.07.17	UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents (PR Newswire)
06.07.17	Lilly Confirms Date and Conference Call for Second-Quarter 2017 Financial Results Announcement (PR Newswire)
06.07.17	Lilly, Purdue University Announce Strategic Research Collaboration - Quick Facts (RTTNews)
05.07.17	Breakfast Technical Briefing on Drug Makers Stocks -- Bristol Myers Squibb, Eli Lilly, AstraZeneca, and Sanofi (PR Newswire)
03.07.17	Eli Lilly Reports Japan Marketing Approval For Olumiant - Quick Facts (RTTNews)
03.07.17	Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis (PR Newswire)
28.06.17	Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications (PR Newswire)
27.06.17	Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications (PR Newswire)
27.06.17	Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour (PR Newswire)
21.06.17	Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego (PR Newswire)
19.06.17	Lilly Declares Third-Quarter 2017 Dividend (PR Newswire)
19.06.17	Lilly and NRAS Launch New Film for RA Awareness Week to Reveal the True Impact of RA (PR Newswire)
16.06.17	Eli Lilly, Incyte Announce Positive Results From Pooled Analysis Of Baricitinib (RTTNews)
16.06.17	Eli Lilly Reports Results From Extension Period Of SPIRIT-P1 Trial (RTTNews)
16.06.17	EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks (PR Newswire)
16.06.17	New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017 (PR Newswire)
16.06.17	Eli Lilly and Company: RA Matters Survey Uncovers What Matters Most to Over 5,000 People Living With Rheumatoid Arthritis (PR Newswire)
16.06.17	ADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good Spirits (RTTNews)
15.06.17	Lilly's Taltz Shows Improvements In Disease Signs And Symptoms In PsA (RTTNews)
15.06.17	EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate... (PR Newswire)
14.06.17	Patented Biotechnology Formulations Resulting in New Generation of Animal Healthcare Medications and Treatments (PR Newswire)
14.06.17	Patented Biotechnology Formulations Resulting in New Generation of Animal Healthcare Medications and Treatments (PR Newswire)
14.06.17	Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017) (PR Newswire)
13.06.17	Jardiance® (empagliflozin) analysis reinforces established safety profile (PR Newswire)
12.06.17	Elanco Releases First-Ever Corporate Social Responsibility Impact Report (PR Newswire)
12.06.17	Boehringer, Eli Lilly To Conduct New Trial Investigating Jardiance Tablets (RTTNews)
12.06.17	Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease (PR Newswire)
10.06.17	Lilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS (PR Newswire)
09.06.17	IDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention (PR Newswire)
08.06.17	Lilly to Present Late-Breaking Data for Galcanezumab and Lasmiditan at the American Headache Society Annual Scientific Meeting (PR Newswire)
08.06.17	Lilly Announces Webcast to Discuss Pain Management Portfolio (PR Newswire)
08.06.17	Lilly Announces Strategic Collaboration with KeyBioscience AG (PR Newswire)
07.06.17	News Alert: Blink Health To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment (PR Newswire)
07.06.17	Blink Health Commits To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment (PR Newswire)
03.06.17	Lilly Builds Upon Body of Data for Abemaciclib with Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival in Advanced Breast Cancer (PR Newswire)
01.06.17	Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at the American Diabetes Association's 77th Scientific Sessions® (PR Newswire)
01.06.17	Eli Lilly CFO Derica Rice To Retire By End Of 2017 - Quick Facts (RTTNews)
01.06.17	Derica Rice to Retire as Lilly Chief Financial Officer (PR Newswire)
01.06.17	Drug Makers Stocks on Investors' Radar -- AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Sanofi (PR Newswire)
31.05.17	Lilly to Participate in Goldman Sachs Global Healthcare Conference (PR Newswire)
31.05.17	Lilly Says Phase 3 RANGE Urothelial Cancer Trial Of CYRAMZA Met Primary Endpoint (RTTNews)
31.05.17	Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA® (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival (PR Newswire)
31.05.17	ALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD (RTTNews)
24.05.17	Elanco Animal Health Works to Bring Products to Small Holder Farmers, Increasing Food Security in East Africa (PR Newswire)
17.05.17	Lilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib and New Portfolio Data at ASCO 2017 (PR Newswire)
16.05.17	Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom (PR Newswire)
12.05.17	Lilly: Galcanezumab For Migraine Met Primary Endpoint In Three Phase 3 Trials (RTTNews)
12.05.17	Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

20.12.24		Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone
20.12.24		Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones
20.12.24		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
20.12.24		Verluste in Europa: Euro STOXX 50 letztendlich leichter
20.12.24		Schwacher Handel: SMI schliesst mit Verlusten
20.12.24		Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus
20.12.24		Handel in Zürich: SMI verbucht Verluste
20.12.24		Börse Frankfurt: So steht der LUS-DAX am Nachmittag

20.12.24

Freundlicher Handel in New York: Dow Jones beendet die Sitzung weit in der Gewinnzone

20.12.24

Handel in New York: Am Freitagnachmittag Gewinne im Dow Jones

20.12.24

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

20.12.24

Verluste in Europa: Euro STOXX 50 letztendlich leichter

20.12.24

Schwacher Handel: SMI schliesst mit Verlusten

20.12.24

Schwache Performance in New York: S&P 500 notiert zum Handelsstart im Minus